Opus Genetics Inc. (NASDAQ: IRD) reported positive three-month data from pediatric participants in its Phase 1/2 clinical trial evaluating OPGx-LCA5 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE